Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06378229

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Led by University Hospital, Ghent · Updated on 2024-09-19

100

Participants Needed

1

Research Sites

136 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Ghent

Lead Sponsor

F

Filament Health Corp.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.

CONDITIONS

Official Title

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of moderate to severe major depressive disorder without psychotic features
  • Failed to respond to 2 or more antidepressants at effective doses for at least 6 weeks
  • Abstinent from alcohol and provide negative urine drug screen on dosing days
  • Female participants must provide a negative pregnancy test on dosing days
  • Medically stable based on lab tests, medical history, vital signs, and ECG
  • QTcF c 450 ms for males or c 470 ms for females and PR-interval < 220 ms on ECG
  • Have a partner willing to participate and cohabiting for at least 1 year
Not Eligible

You will not qualify if you...

  • Current or past diagnosis of major depressive episode with psychotic features
  • Psychotic disorder (except brief substance-induced psychosis)
  • Bipolar disorder type 1 or 2
  • Drug or alcohol dependence syndrome
  • Cluster B personality disorder
  • PTSD diagnosis
  • Family history of psychosis or bipolar disorder in a first-degree relative
  • Active suicidal thoughts
  • Depression caused by other medical conditions
  • Recent stroke or myocardial infarction within 1 year
  • Uncontrolled hypertension or significant arrhythmia within 1 year
  • Uncontrolled insulin-dependent diabetes or epilepsy
  • Significant biochemical or ECG abnormalities
  • Current use of Lithium, Disulfiram, MAOIs, or certain enzyme inhibitors
  • Prior vagal nerve stimulation or deep brain stimulation treatment
  • Women of childbearing potential not using effective contraception
  • Pregnant or breastfeeding women
  • Unable to give informed consent
  • Currently enrolled in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ghent University Hospital

Ghent, Oost-Vlaanderen, Belgium, 9000

Actively Recruiting

Loading map...

Research Team

C

Cisse Geleyn, dr.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Psilocybin for Hospitalized Patients with Treatment-resistant Depression | DecenTrialz